Tert-butyl 2-(5-bromo-4-oxo-3-phenylquinazolin-2-yl)pyrrolidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Tert-butyl 2-(5-bromo-4-oxo-3-phenylquinazolin-2-yl)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl 2-(5-bromo-4-oxo-3-phenylquinazolin-2-yl)pyrrolidine-1-carboxylate
• 化学式: C₂₃H₂₄BrN₃O₃
• 分子量: 470.4
• InChiKey: ZDWHAIHRAINOCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  62.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] QUINAZOLIN-4-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLIN-4-ONE
  申请人：NOVARTIS AG

  公开号：WO2014128612A1

  公开（公告）日：2014-08-28

  The invention relates to quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, Formula (I) wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.

  该发明涉及式(I)的喹唑啉-4-酮化合物和/或其药用可接受的盐和/或溶剂，式(I)中R1、R2、R3、R5、R6和L的定义如描述中所述。这些化合物适用于治疗由I类PI3K激酶活性介导的疾病或疾病。
• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20160024054A1

  公开（公告）日：2016-01-28

  The present disclosure provides phosphatidylinositol 3 -kinase (PBK) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.

  本公开提供公式（J）的磷脂酰肌醇3-激酶（PBK）抑制剂，或其药学上可接受的盐，其中A、n、m、R1、R2、R3、R4、R5、R6和R7如本文所定义。这些化合物可用于治疗由一个或多个PI3K亚型介导的疾病。本公开还提供包括公式（J）的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗由一个或多个PI3K亚型介导的疾病的方法。
• US9765060B2
  申请人：——

  公开号：US9765060B2

  公开（公告）日：2017-09-19